[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"olfactory-impairment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:olfactory-impairment":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100530811","sinus-disease-in-young-children-with-cystic-fibrosis-100530811",false,"NCT06191640","Sinus Disease in Young Children With Cystic Fibrosis","Inclusion Criteria:\n\nHEMT Group:\n\n* Children with documentation of a CF diagnosis\n* Age 2-8 years old at first study visit\n* CFTR mutation consistent with FDA labeled indication of highly effective modulator therapy (ivacaftor or elexacaftor\u002Ftezacaftor\u002Fivacaftor)\n* Clinician intent to prescribe ivacaftor or ETI so that enrollment is before start of HEMT\n\nNon-HEMT\u002FControl Group:\n\n* Children with documentation of a CF diagnosis\n* Age 2-8 years at first study visit\n* Ineligible for highly effective modulator therapy (ivacaftor or elexacaftor\u002Ftezacaftor\u002Fivacaftor) based on CFTR mutation or clinical decision not to initiate HEMT if eligible\n\nExclusion Criteria:\n\nFor Both Groups:\n\n* Use of an investigational drug within 28 days prior to the first study visit\n* Use of ivacaftor or elexacaftor\u002Ftezacaftor\u002Fivacaftor within the 180 days prior to and including the first study visit\n* Use of chronic oral corticosteroids within the 28 days prior to and including the first study visit.\n* Sinus surgery within 180 days prior to the first study visit","ALL","2 Years","8 Years",{"count":19,"type":20},80,"ESTIMATED","OBSERVATIONAL","This is a prospective, observational study examining the impact of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators on chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) in young children with cystic fibrosis (YCwCF). This study involves two groups: children 2-8 years old, inclusive at initial visit, receiving highly effective modulator therapy (HEMT), and a control group of children 2-8 years old, inclusive at initial visit, not receiving HEMT. Outcomes will include sinus magnetic resonance imaging (MRI) scans, olfactory tests, and quality of life surveys obtained over a two-year period.",[24,25,26,27,28],"Cystic Fibrosis in Children","Cystic Fibrosis","Chronic Rhinosinusitis (Diagnosis)","Olfactory Disorder","Olfactory Impairment",[25,30,31],"Chronic Rhinosinusitis","Olfactory Dysfunction","RECRUITING","2026-05-06",{"date":35,"type":36},"2026-05-11","ACTUAL",{"date":38,"type":36},"2023-04-12",{"date":40,"type":20},"2029-06-30",{"name":42,"class":43},"University of California, Los Angeles","OTHER",6,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100467236","olfactory-training-on-smell-dysfunction-patients-in-hk-100467236","NCT05364125","Olfactory Training on Smell Dysfunction Patients in HK","Effect of Olfactory Training on Olfactory Dysfunction Patients in Hong Kong Population","Inclusion Criteria:\n\n* Olfactory dysfunction \\> 6 months and \\\u003C 5 years\n\nExclusion Criteria:\n\n* History of significant head injury (fracture, ICH)\n* History of brain surgery\n* History of nasal surgery\n* Active nasal disease\n* Active neurological disease\n* Poor premorbid status\u002F non-communicable patients\n* Mentally incompetent patients\n* \\\u003C18 years' old\n* Pregnancy\n* Hypersensitivity to the aromatic substance.","18 Years","70 Years",{"count":19,"type":20},"INTERVENTIONAL",[57],"NA","* Causes of olfactory dysfunction can be classified into conductive and sensorineural causes.\n* Conductive causes are mainly due to structural nasal problem, which can be treated by nasal surgery\n* Sensorineural causes included post-infection, post-head injury, post Head and Neck irradiation and other central nervous system diseases.\n* Olfactory Training is well established treatment for sensorineural olfactory dysfunction in foreign countries.\n* Olfactory Training by neurological chemosensory stimulation using aromatic substances delivered via electronic portable aromatic rehabilitation (EPAR) diffuser was proved to be effective treatment in COVID-19 related olfactory dysfunction in recent Hong Kong study.\n* However, there is a lack of local study on the effect of Olfactory Training in other non-COVID-19 sensorineural causes of olfactory dysfunction in Hong Kong population.",[60,61,62,63,28,64,65],"Olfaction Disorders","Smell Disorders","Anosmia","Hyposmia","Smell Loss","Smell Dysfunction","2025-05-28",{"date":68,"type":36},"2025-06-03",{"date":70,"type":36},"2022-07-01",{"date":72,"type":20},"2027-06-30",{"name":74,"class":43},"Pamela Youde Nethersole Eastern Hospital",1]